Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?
Open accessAbstract
Epidemiological and basic science evidence suggest a possible shared pathophysiology between type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD). It has even been hypothesized that AD might be ‘type 3 diabetes’. The present review summarizes some of the evidence for the possible link, putative biochemical pathways and ongoing clinical trials of antidiabetic drugs in AD patients. The primary and review literature were searched for articles published in peer‐reviewed sources that were related to a putative connection between T2DM and AD. In addition, public sources of clinical trials were searched for the relevant information regarding the testing of antidiabetic drugs in AD patients. The evidence for a connection between T2DM and AD is based upon a variety of diverse studies, but definitive biochemical mechanisms remain unknown. Additional study is needed to prove the existence or the extent of a link between T2DM and AD, but sufficient evidence exists to warrant further study. Presently, AD patients might benefit from treatment with pharmacotherapy currently used to treat T2DM and clinical trials of such therapy are currently underway.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
T2D has also been identified as a risk factor for Alzheimer's and Parkinson's diseases.
“T2D has also been identified as a risk factor for Alzheimer’s and Parkinson’s diseases.42,43”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [42]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 158 · Cited by 352
Research works printed but not linked: 4
- Davis SN, Granner DK. Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas. In: Gilman and Goodman's the Pharmacological Basis of Therapeutics, 9th edn, eds Hardman JG, Gilman AG, Limbird LE. New York: McGraw-Hill, 1996; 1487-517.
- Freychet P. Insulin receptors and insulin action in the nervous system. Diabetes Metab Res Rev 2000; 16: 390-2.
- Hardie G, Hanks S, authors, eds. The Protein Kinase FactsBook, Vol. 1. London: Academic Press, 1995.
- Hardie G, Hanks S, authors, eds. The Protein Kinase FactsBook, Vol. 2. London: Academic Press, 1995.
- Authors
- Akter, K., Lanza, E. A., Martin, S. A., Myronyuk, N., Rua, M., & Raffa, R. B.
- Affiliations
- Temple University (US)
- Corresponding author
- Raffa, Robert B.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2011-02
- Volume
- 71
- Issue
- 3
- Pages
- 365-376
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- PMC
- PMC3045545
- OpenAlex
- W1515929023
- Cited by
- 352
- References
- 158
- Citations by year
- 2026: 9 · 2025: 21 · 2024: 19 · 2023: 24 · 2022: 29 · 2021: 25 · 2020: 29 · 2019: 25 · 2018: 20 · 2017: 26 · 2016: 27 · 2015: 25 · 2014: 26 · 2013: 23 · 2012: 18
- FWCI
- 1.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- British Journal of Clinical Pharmacology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- type 2 diabetes, Alzheimer's disease, shared pathophysiology, type 3 diabetes, antidiabetic drugs, clinical trials, metabolic pathways
- MeSH terms
- Alzheimer Disease, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Treatment Outcome, Diabetes Complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
